The binding affinities of gaNODeric acid DM and gaNODeric acid Z (??Gbind, -16.83 and-10.99 kcal mol-1) are comparable to that of current commercial drug oseltamivir (-23.62 kcal mol-1);GaNODeric acid DM is a potential source of anti-influenza ingredient, with novel binding pattern and advantage over oseltamivir, it has steric hindrance on the 150 cavity of N1 protein, and exerts activities acROSs the H274Y and N294S mutations, is the attractive candidates of novel neuraminidase (NA) inhibitors.GaNODeric acid zeta has cytotoxicity in vitro against Meth-A and LLC cell lines.

The binding affinities of ganoderic acid DM and ganoderic acid Z (I?Gbind, -16.83 and-10.99 kcal mol-1) are comparable to that of current commercial drug oseltamivir (-23.62 kcal mol-1);Ganoderic acid DM is a potential source of anti-influenza ingredient, with novel binding pattern and advantage over oseltamivir, it has steric hindrance on the 150 cavity of N1 protein, and exerts activities across the H274Y and N294S mutations, is the attractive candidates of novel neuraminidase (NA) inhibitors.Ganoderic acid zeta has cytotoxicity in vitro against Meth-A and LLC cell lines.

294674-09-2

C30H42O7

514.659

Ganoderic acid Z

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years